Toll Free: 1-888-928-9744

Follicular Lymphoma - Pipeline Review, H1 2016

Published: May 25, 2016 | Pages: 542 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Follicular Lymphoma - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Follicular Lymphoma - Pipeline Review, H1 2016', provides an overview of the Follicular Lymphoma pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Follicular Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Follicular Lymphoma and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Follicular Lymphoma
- The report reviews pipeline therapeutics for Follicular Lymphoma by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Follicular Lymphoma therapeutics and enlists all their major and minor projects
- The report assesses Follicular Lymphoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Follicular Lymphoma

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Follicular Lymphoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Follicular Lymphoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 Introduction 6 Follicular Lymphoma Overview 7 Therapeutics Development 8 Follicular Lymphoma - Therapeutics under Development by Companies 10 Follicular Lymphoma - Therapeutics under Investigation by Universities/Institutes 14 Follicular Lymphoma - Pipeline Products Glance 15 Follicular Lymphoma - Products under Development by Companies 18 Follicular Lymphoma - Products under Investigation by Universities/Institutes 24 Follicular Lymphoma - Companies Involved in Therapeutics Development 25 Follicular Lymphoma - Therapeutics Assessment 76 Drug Profiles 91 Follicular Lymphoma - Recent Pipeline Updates 303 Follicular Lymphoma - Dormant Projects 520 Follicular Lymphoma - Discontinued Products 523 Follicular Lymphoma - Product Development Milestones 524 Appendix 532
List of Tables
Number of Products under Development for Follicular Lymphoma, H1 2016 17 Number of Products under Development for Follicular Lymphoma - Comparative Analysis, H1 2016 18 Number of Products under Development by Companies, H1 2016 19 Number of Products under Development by Companies, H1 2016 (Contd..1) 20 Number of Products under Development by Companies, H1 2016 (Contd..2) 21 Number of Products under Development by Companies, H1 2016 (Contd..3) 22 Number of Products under Investigation by Universities/Institutes, H1 2016 23 Comparative Analysis by Late Stage Development, H1 2016 24 Comparative Analysis by Clinical Stage Development, H1 2016 25 Comparative Analysis by Early Stage Development, H1 2016 26 Products under Development by Companies, H1 2016 27 Products under Development by Companies, H1 2016 (Contd..1) 28 Products under Development by Companies, H1 2016 (Contd..2) 29 Products under Development by Companies, H1 2016 (Contd..3) 30 Products under Development by Companies, H1 2016 (Contd..4) 31 Products under Development by Companies, H1 2016 (Contd..5) 32 Products under Investigation by Universities/Institutes, H1 2016 33 Follicular Lymphoma - Pipeline by AbbVie Inc., H1 2016 34 Follicular Lymphoma - Pipeline by Affimed GmbH , H1 2016 35 Follicular Lymphoma - Pipeline by Bayer AG, H1 2016 36 Follicular Lymphoma - Pipeline by BeiGene, Ltd., H1 2016 37 Follicular Lymphoma - Pipeline by Bio-Path Holdings, Inc., H1 2016 38 Follicular Lymphoma - Pipeline by Biocon Limited, H1 2016 39 Follicular Lymphoma - Pipeline by Biogenomics Limited, H1 2016 40 Follicular Lymphoma - Pipeline by Boehringer Ingelheim GmbH, H1 2016 41 Follicular Lymphoma - Pipeline by Bristol-Myers Squibb Company, H1 2016 42 Follicular Lymphoma - Pipeline by Celgene Corporation, H1 2016 43 Follicular Lymphoma - Pipeline by Celldex Therapeutics, Inc., H1 2016 44 Follicular Lymphoma - Pipeline by Celltrion, Inc., H1 2016 45 Follicular Lymphoma - Pipeline by Cellular Biomedicine Group, Inc., H1 2016 46 Follicular Lymphoma - Pipeline by Coherus BioSciences, Inc., H1 2016 47 Follicular Lymphoma - Pipeline by CTI BioPharma Corp., H1 2016 48 Follicular Lymphoma - Pipeline by Curis, Inc., H1 2016 49 Follicular Lymphoma - Pipeline by Dynavax Technologies Corporation, H1 2016 50 Follicular Lymphoma - Pipeline by Eisai Co., Ltd., H1 2016 51 Follicular Lymphoma - Pipeline by EpiZyme, Inc., H1 2016 52 Follicular Lymphoma - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 53 Follicular Lymphoma - Pipeline by Genentech, Inc., H1 2016 54 Follicular Lymphoma - Pipeline by Gilead Sciences, Inc., H1 2016 55 Follicular Lymphoma - Pipeline by GlaxoSmithKline Plc, H1 2016 56 Follicular Lymphoma - Pipeline by Hutchison MediPharma Limited, H1 2016 57 Follicular Lymphoma - Pipeline by Immune Design Corp., H1 2016 58 Follicular Lymphoma - Pipeline by ImmunoGen, Inc., H1 2016 59 Follicular Lymphoma - Pipeline by Immunomedics, Inc., H1 2016 60 Follicular Lymphoma - Pipeline by Infinity Pharmaceuticals, Inc., H1 2016 61 Follicular Lymphoma - Pipeline by Johnson & Johnson, H1 2016 62 Follicular Lymphoma - Pipeline by Juno Therapeutics Inc., H1 2016 63 Follicular Lymphoma - Pipeline by Karyopharm Therapeutics, Inc., H1 2016 64 Follicular Lymphoma - Pipeline by Kite Pharma, Inc., H1 2016 65 Follicular Lymphoma - Pipeline by Les Laboratoires Servier SAS, H1 2016 66 Follicular Lymphoma - Pipeline by MedImmune, LLC, H1 2016 67 Follicular Lymphoma - Pipeline by Medivation, Inc., H1 2016 68 Follicular Lymphoma - Pipeline by MEI Pharma, Inc., H1 2016 69 Follicular Lymphoma - Pipeline by Merck & Co., Inc., H1 2016 70 Follicular Lymphoma - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016 71 Follicular Lymphoma - Pipeline by Mirati Therapeutics Inc., H1 2016 72 Follicular Lymphoma - Pipeline by MorphoSys AG, H1 2016 73 Follicular Lymphoma - Pipeline by Nordic Nanovector ASA, H1 2016 74 Follicular Lymphoma - Pipeline by Novartis AG, H1 2016 75 Follicular Lymphoma - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 76 Follicular Lymphoma - Pipeline by Pfizer Inc., H1 2016 77 Follicular Lymphoma - Pipeline by Pharmacyclics, Inc., H1 2016 78 Follicular Lymphoma - Pipeline by Portola Pharmaceuticals, Inc., H1 2016 79 Follicular Lymphoma - Pipeline by ProNAi Therapeutics, Inc., H1 2016 80 Follicular Lymphoma - Pipeline by Sandoz International GmbH, H1 2016 81 Follicular Lymphoma - Pipeline by Seattle Genetics, Inc., H1 2016 82 Follicular Lymphoma - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 83 Follicular Lymphoma - Pipeline by TG Therapeutics, Inc., H1 2016 84 Assessment by Monotherapy Products, H1 2016 85 Assessment by Combination Products, H1 2016 86 Number of Products by Stage and Target, H1 2016 88 Number of Products by Stage and Mechanism of Action, H1 2016 93 Number of Products by Stage and Route of Administration, H1 2016 97 Number of Products by Stage and Molecule Type, H1 2016 99 Follicular Lymphoma Therapeutics - Recent Pipeline Updates, H1 2016 312 Follicular Lymphoma - Dormant Projects, H1 2016 529 Follicular Lymphoma - Dormant Projects (Contd..1), H1 2016 530 Follicular Lymphoma - Dormant Projects (Contd..2), H1 2016 531 Follicular Lymphoma - Discontinued Products, H1 2016 532


List of Figures
Number of Products under Development for Follicular Lymphoma, H1 2016 17 Number of Products under Development for Follicular Lymphoma - Comparative Analysis, H1 2016 18 Number of Products under Development by Companies, H1 2016 19 Comparative Analysis by Late Stage Development, H1 2016 24 Comparative Analysis by Clinical Stage Development, H1 2016 25 Comparative Analysis by Early Stage Products, H1 2016 26 Assessment by Monotherapy Products, H1 2016 85 Number of Products by Top 10 Targets, H1 2016 87 Number of Products by Stage and Top 10 Targets, H1 2016 87 Number of Products by Top 10 Mechanism of Actions, H1 2016 92 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 92 Number of Products by Routes of Administration, H1 2016 96 Number of Products by Stage and Routes of Administration, H1 2016 96 Number of Products by Top 10 Molecule Types, H1 2016 98 Number of Products by Stage and Top 10 Molecule Types, H1 2016 98

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global embedded system market is projected to be valued at USD 214.39 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising demand from end-use industries such as automotive and healthcare coupled with emergence of Internet o

Read More...

Global Automated Test Equipment (ATE) market is expected to be valued at USD 4.48 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing design complexity coupled with need for effective testing is expected to drive the gl

Read More...

Global fluorotelomers market size is anticipated to be valued at USD 539.3 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing application scope in fire fighting systems owing to growing safety concerns is likely to dri

Read More...

Global fingerprint access control systems market size is estimated to reach USD 4.4 billion by 2022, as per a new research report by Radiant Insights, Inc. Growing safety and security concerns of individual as well as organization is projected to dri

Read More...

Global automotive coatings market size is likely to be valued at USD 27.7 billion by 2022; as per a new research report by Radiant Insights, Inc. Vehicle aesthetics, UV radiation and temperature variation protection and enhance durability are certain

Read More...
Choose License Type
Single User - US $2000
Multi User - US $4000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify